Comparison · NCT01002742-a4fbb02e
Mycophenolate Mofetil vs Placebo: Incidence of GVHD Flares Requiring Increased Therapy
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Mycophenolate Mofetil vs Placebo: Incidence of GVHD Flares Requiring Increased Therapy. Trial comparisons, record NCT01002742-a4fbb02e. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01002742-a4fbb02e
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.069 | 0.0354 | 0.13 | wilson | |
| Risk in group 2 | 0.134 | 0.0845 | 0.207 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0655 | -0.146 | 0.0136 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.513 | 0.228 | 1.15 | log | |
| Odds ratio, group 1 over group 2 | 0.477 | 0.196 | 1.16 | log | |
| Number needed to treat, for one fewer participant with the outcome on Mycophenolate Mofetil than on Placebo | 15.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Mycophenolate Mofetil | Corticosteroids with Mycophenolate Mofetil | 8 | 116 | OG001 |
| Group 2 | Placebo | Corticosteroids with placebo | 16 | 119 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Incidence of GVHD Flares Requiring Increased Therapy
- Description
Flares are defined as any progression of acute GVHD after an initial response (i.e., earlier CR or PR) that requires re-escalation of steroid dosing, or initiation of additional topical or systemic therapy.
- Time frame
- Day 90
- Population
Source ClinicalTrials.gov
Trial
- Title
- Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
- NCT number
- NCT01002742
- Phases
- PHASE3
- Conditions
- Graft-versus-Host Disease, Immune System Disorders
- Interventions
- Mycophenolate Mofetil, Placebo
- Lead sponsor
- Medical College of Wisconsin
- Results first posted
- 2016-05-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01002742?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01002742-a4fbb02e